These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28220805)

  • 1. Meta-analysis of metabolic syndrome and prostate cancer.
    Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
    Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic syndrome is associated with more aggressive prostate cancer.
    Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
    Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.
    Morlacco A; Dal Moro F; Rangel LJ; Carlson RE; Schulte PJ; Jeffrey KR
    Urol Oncol; 2018 Dec; 36(12):528.e1-528.e6. PubMed ID: 30446466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
    Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
    Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
    Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
    J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer.
    Russo GI; Cimino S; Giranio G; Regis F; Favilla V; Privitera S; Motta F; Caltabiano R; Stenzl A; Todenhöfer T; Morgia G
    Urol Oncol; 2018 May; 36(5):240.e21-240.e26. PubMed ID: 29429896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.
    Chen Z; Deng J; Yan Y; Li M; Chen C; Chen C; Zhao S; Song T; Liu T; Wen X; Yao Y
    Horm Cancer; 2018 Aug; 9(4):278-287. PubMed ID: 29948970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.
    Zhang GM; Zhu Y; Dong DH; Han CT; Gu CY; Gu WJ; Qin XJ; Sun LJ; Ye DW
    Asian J Androl; 2015; 17(5):839-44. PubMed ID: 25652638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
    De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
    Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
    Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.
    Bhindi B; Xie WY; Kulkarni GS; Hamilton RJ; Nesbitt M; Finelli A; Zlotta AR; Evans A; van der Kwast TH; Alibhai SM; Trachtenberg J; Fleshner NE
    Urology; 2016 Jul; 93():77-85. PubMed ID: 27015944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study.
    Liu Z; Zhu X; He J; Lu J
    BMC Cancer; 2023 Jan; 23(1):50. PubMed ID: 36641426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.
    Macleod LC; Chery LJ; Hu EY; Zeliadt SB; Holt SK; Lin DW; Porter MP; Gore JL; Wright JL
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):190-5. PubMed ID: 25823651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
    Rieken M; Shariat SF; Kluth LA; Fajkovic H; Rink M; Karakiewicz PI; Seitz C; Briganti A; Rouprêt M; Loidl W; Trinh QD; Bachmann A; Pourmand G
    Eur Urol; 2015 Dec; 68(6):949-56. PubMed ID: 26050111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.